Helicobacter Pylori Non-invasive Testing Market to Exceed USD 788.2 million by 2031, with a CAGR of 4.2%: Transparency Market Research, Inc
22 févr. 2024 05h50 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. -The global helicobacter pylori (H. Pylori) non-invasive testing market is estimated to surge...
Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica
23 janv. 2024 08h19 HE
|
Biomerica, Inc.
Mr. Kenny has significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Kenny most recently served as CEO of Meridian Bioscience where he successfully built...
Antibody Drug Conjugates Market Revenue to Hit $29.6 Billion, Globally, by 2030 – Exclusive Study by The Insight Partners
09 oct. 2023 08h04 HE
|
The Insight Partners
Pune, India, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Antibody drug conjugates (ADC) are one of the fastest growing anticancer drugs. It is typically composed of a monoclonal antibody (mAbs) covalently...
Gastric Cancer Diagnostic Procedure Market Size Forecasts at 6.5% CAGR during (2022-2028) - Deep Dive Analysis of 18+ Countries across 5 Key Regions, 50+ Companies Scrutinized | The Insight Partners
02 mars 2023 09h55 HE
|
The Insight Partners
New York, March 02, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Gastric Cancer Diagnostic Procedure Market Size, Share, Growth, Trends and Global Forecasts to 2028 - COVID-19 Impact...
Helicobacter Pylori Non-invasive Testing Market Revenue to Cross $800.04Mn, Globally, by 2028 to Growing at 4.4% CAGR – Study by The Insight Partners
24 août 2022 06h00 HE
|
The Insight Partners
New York, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market Forecast to 2028 – COVID-19 Impact...
Biomerica Announces FDA Submission For a Test to Detect Helicobacter pylori (H. pylori), a Bacteria That Infects Approximately 35% of the US Population
26 avr. 2022 08h19 HE
|
Biomerica, Inc.
Gastric cancer is the third most common cause of cancer related death in the world and over 80% of gastric cancers are attributed to H. pylori bacterial infection H. pylori infection is also a major...
Biomerica Signs Exclusive Distribution Agreement in Canada for its New and Proprietary Helicobacter Pylori (H. pylori) Test, hp+detect™
24 juin 2021 08h19 HE
|
Biomerica, Inc.
Prevalence of H. pylori infection in the United States is approximately 35% to 40% of the population IRVINE, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced...
RedHill Biopharma Increases Patient Access to Talicia® with EnvisionRx Formularies
27 juil. 2020 07h00 HE
|
RedHill Biopharma Ltd.
Talicia® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection designed as a first-line option to address the high and growing resistance of H. pylori to...
RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults
04 nov. 2019 06h05 HE
|
RedHill Biopharma Ltd.
RedHill plans to launch Talicia®1 in the U.S. in Q1/2020 for the treatment of H. pylori infection in adults, targeting more than two million patients estimated to be treated for H. pylori infection...
RedHill Biopharma Submits New Drug Application for Talicia® for H. pylori Infection
07 mai 2019 06h05 HE
|
RedHill Biopharma Ltd.
The NDA follows a recent positive pre-NDA meeting with the FDA The NDA for Talicia® is eligible for six-month priority review Talicia® is eligible for a total of eight years of U.S. market...